{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:16:41Z","timestamp":1790090201440,"version":"4.0.1"},"reference-count":282,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.intimp.2025.114692","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T23:07:13Z","timestamp":1745276833000},"page":"114692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson's disease: From pathogenesis to potential therapeutic strategies"],"prefix":"10.1016","volume":"156","author":[{"given":"Ahmed M.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114692_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2025.114692_bb0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-0036-1585097","article-title":"Parkinsonism","volume":"36","author":"Keener","year":"2016","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.intimp.2025.114692_bb0015","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that \u03b1-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/BJ20150617","article-title":"Amyloid fibrils are the molecular trigger of inflammation in Parkinson\u2019s disease","volume":"471","author":"Gustot","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.intimp.2025.114692_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114361","article-title":"1,2,4-Trimethoxybenzene ameliorates depression-like behaviors by inhibiting the activation of NLRP3 inflammasome","volume":"151","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10060912","article-title":"The future of targeted gene-based treatment strategies and biomarkers in parkinson\u2019s disease","volume":"10","author":"Polissidis","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2025.114692_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents -synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0040","doi-asserted-by":"crossref","DOI":"10.1097\/HM9.0000000000000088","article-title":"Crocus sativus L. produces anti-inflammatory effects and regulates NLRP3\u2013NF-\u03baB pathway","author":"Yang","year":"2024","journal-title":"Acupuncture and Herbal Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114442","article-title":"Farrerol alleviates cognitive impairments in chronic cerebral hypoperfusion via suppressing NLRP3 inflammasome-mediated pyroptosis","volume":"153","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0349-x","article-title":"Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway","volume":"15","author":"Park","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.intimp.2025.114692_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105543","article-title":"ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson\u2019s disease","volume":"161","author":"Nordstr\u00f6m","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00441-004-0974-7","article-title":"Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells","volume":"318","author":"Perlmann","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.intimp.2025.114692_bb0070","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1101\/gad.276003","article-title":"Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells","volume":"17","author":"Wall\u00e9n-Mackenzie","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.intimp.2025.114692_bb0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrneurol.2013.209","article-title":"NURR1 in Parkinson disease\u2014from pathogenesis to therapeutic potential","volume":"9","author":"Decressac","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.intimp.2025.114692_bb0080","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/WNR.0b013e3282ffda48","article-title":"Nurr1 transcriptionally regulates the expression of alpha-synuclein","volume":"19","author":"Yang","year":"2008","journal-title":"Neuroreport"},{"key":"10.1016\/j.intimp.2025.114692_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416184","article-title":"Advances in NURR1-regulated Neuroinflammation associated with Parkinson\u2019s disease","volume":"23","author":"Al-Nusaif","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0090","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s12035-020-02198-5","article-title":"NLRP3 Inflammasome inhibition prevents \u03b1-Synuclein pathology by relieving autophagy dysfunction in chronic MPTP\u2013treated NLRP3 knockout mice","volume":"58","author":"Ou","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2025.114692_bb0095","series-title":"Nurr1 Is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons","author":"Kadkhodaei","year":"2009"},{"key":"10.1016\/j.intimp.2025.114692_bb0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0166-2236(97)01213-7","article-title":"The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease","volume":"21","author":"Clayton","year":"1998","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0105","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024091","article-title":"Cell biology and pathophysiology of \u03b1-synuclein","volume":"8","author":"Burr\u00e9","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0110","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/hmg\/10.9.919","article-title":"Inducible expression of mutant \u03b1-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis","volume":"10","author":"Tanaka","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.intimp.2025.114692_bb0115","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/s41467-021-26433-2","article-title":"The hereditary mutation G51D unlocks a distinct fibril strain transmissible to wild-type \u03b1-synuclein","volume":"12","author":"Sun","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0120","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1073\/pnas.1917914117","article-title":"The \u03b1-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure","volume":"117","author":"Boyer","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41422-020-0299-4","article-title":"Cryo-EM structure of full-length \u03b1-synuclein amyloid fibril with Parkinson\u2019s disease familial A53T mutation","volume":"30","author":"Sun","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2025.114692_bb0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.brainres.2015.06.002","article-title":"Post-translational modification of alpha- synuclein in Parkinson\u2019s disease","volume":"1628","author":"Barrett","year":"2015","journal-title":"J. Brain Res."},{"key":"10.1016\/j.intimp.2025.114692_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1808-9","article-title":"Regulation of \u03b1-synuclein by chaperones in mammalian cells","volume":"577","author":"Burmann","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.114692_bb0140","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.neuroscience.2012.01.028","article-title":"Lewy-like aggregation of \u03b1-synuclein reduces protein phosphatase 2A activity in vitro and in vivo","volume":"207","author":"Wu","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.intimp.2025.114692_bb0145","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","article-title":"Enhanced phosphatase activity attenuates \u03b1-synucleinopathy in a mouse model","volume":"31","author":"Lee","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0150","doi-asserted-by":"crossref","first-page":"20305","DOI":"10.1073\/pnas.1922741117","article-title":"Parkinson\u2019s disease-related phosphorylation at Tyr39 rearranges \u03b1-synuclein amyloid fibril structure revealed by cryo-EM","volume":"117","author":"Zhao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0155","doi-asserted-by":"crossref","first-page":"47746","DOI":"10.1074\/jbc.M408906200","article-title":"Functional consequences of \u03b1-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation","volume":"279","author":"Hodara","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0160","doi-asserted-by":"crossref","first-page":"7152","DOI":"10.1021\/ja2009554","article-title":"Allostery in a disordered protein: oxidative modifications to \u03b1-synuclein act distally to regulate membrane binding","volume":"133","author":"Sevcsik","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.intimp.2025.114692_bb0165","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nchem.2361","article-title":"O-GlcNAc modification blocks the aggregation and toxicity of the protein \u03b1-synuclein associated with Parkinson\u2019s disease","volume":"7","author":"Marotta","year":"2015","journal-title":"Nat. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12081057","article-title":"The significance of NLRP Inflammasome in neuropsychiatric disorders","volume":"12","author":"Shen","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0175","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 Inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.114692_bb0180","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","article-title":"NLRP3 inflammasome activation and cell death","volume":"18","author":"Huang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.114692_bb0185","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2025.114692_bb0190","first-page":"929","article-title":"Effect of NLRP3\/GSDMD\/IL-1\u03b2 pathway in post epileptic depressive behavior of developmental rats and its possible intervention approaches","volume":"45","author":"Wen-Jie","year":"2020","journal-title":"Med. J. Chinese People's Liberation Army"},{"key":"10.1016\/j.intimp.2025.114692_bb0195","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s10753-023-01918-y","article-title":"Investigating the TLR4\/TAK1\/IRF7 axis in NLRP3-mediated Pyroptosis in Parkinson\u2019s disease","volume":"47","author":"Quan","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2025.114692_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115735","article-title":"The interplay between \u03b1-Synuclein and NLRP3 inflammasome in Parkinson\u2019s disease","volume":"168","author":"Huang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.114692_bb0205","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.114692_bb0210","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1080\/15548627.2020.1719723","article-title":"Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice","volume":"16","author":"Cheng","year":"2020","journal-title":"Autophagy"},{"issue":"2017","key":"10.1016\/j.intimp.2025.114692_bb0215","first-page":"1255","article-title":"Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease","volume":"357","author":"Burbulla","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.114692_bb0220","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12974-021-02349-y","article-title":"p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson\u2019s disease","volume":"18","author":"Chen","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"2004","key":"10.1016\/j.intimp.2025.114692_bb0225","first-page":"1292","article-title":"Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.114692_bb0230","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.21037\/atm-22-5159","article-title":"BAG3 promotes autophagy and suppresses NLRP3 inflammasome activation in Parkinson\u2019s disease","volume":"10","author":"Ying","year":"2022","journal-title":"Ann Transl. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0235","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1080\/15548627.2021.1965426","article-title":"USP5 attenuates NLRP3 inflammasome activation by promoting autophagic degradation of NLRP3","volume":"18","author":"Cai","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.intimp.2025.114692_bb0240","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.3390\/ijms23073705","article-title":"Atypical ubiquitination and Parkinson\u2019s disease","volume":"23","author":"Buneeva","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0245","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","article-title":"Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions","volume":"35","author":"Chu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0250","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1080\/15548627.2019.1596481","article-title":"Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease","volume":"15","author":"Han","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.intimp.2025.114692_bb0255","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/15548627.2022.2107314","article-title":"USP22 suppresses the NLRP3 inflammasome by degrading NLRP3 via ATG5-dependent autophagy","volume":"19","author":"Di","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.intimp.2025.114692_bb0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbi.2019.06.042","article-title":"Toll-like receptors and their therapeutic potential in Parkinson\u2019s disease and \u03b1-synucleinopathies","volume":"81","author":"Kouli","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2025.114692_bb0265","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","article-title":"Toll-like receptor 2 is increased in neurons in Parkinson\u2019s disease brain and may contribute to alpha-synuclein pathology","volume":"133","author":"Dzamko","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2025.114692_bb0270","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/ncomms2534","article-title":"Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia","volume":"4","author":"Kim","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0275","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/glia.23970","article-title":"\u0391-Synuclein evokes NLRP3 inflammasome-mediated IL-1\u03b2 secretion from primary human microglia","volume":"69","author":"Pike","year":"2021","journal-title":"Glia"},{"key":"10.1016\/j.intimp.2025.114692_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-024-00448-3","article-title":"Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson\u2019s model","volume":"13","author":"Weiss","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.intimp.2025.114692_bb0285","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00401-018-1907-y","article-title":"Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson\u2019s disease pathogenesis","volume":"137","author":"Hughes","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2025.114692_bb0290","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","article-title":"Microglia clear neuron-released \u03b1-synuclein via selective autophagy and prevent neurodegeneration","volume":"11","author":"Choi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0295","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbi.2018.12.003","article-title":"TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson\u2019s diseases in vivo model","volume":"76","author":"Campolo","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2025.114692_bb0300","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13024-016-0094-3","article-title":"MicroRNA-7 targets nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson\u2019s disease","volume":"11","author":"Zhou","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.intimp.2025.114692_bb0305","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00018-017-2541-x","article-title":"Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production","volume":"74","author":"Tapias","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0310","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41419-019-2091-2","article-title":"Mitochondrial damage by \u03b1-synuclein causes cell death in human dopaminergic neurons","volume":"10","author":"Ganjam","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0315","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/scitranslmed.aaf3634","article-title":"\u0391-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease","volume":"8","author":"Di Maio","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0320","doi-asserted-by":"crossref","first-page":"32208","DOI":"10.1074\/jbc.M111.280446","article-title":"Interaction between the human mitochondrial import receptors Tom20 and Tom70 in vitro suggests a chaperone displacement mechanism","volume":"286","author":"Fan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imr.12286","article-title":"Initiation and perpetuation of NLRP3 inflammasome activation and assembly","volume":"265","author":"Elliott","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.114692_bb0330","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1074\/jbc.M710012200","article-title":"Mitochondrial import and accumulation of \u03b1-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain","volume":"283","author":"Devi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0335","doi-asserted-by":"crossref","first-page":"10190","DOI":"10.1128\/MCB.25.22.10190-10201.2005","article-title":"Mitochondrial lipid abnormality and Electron transport chain impairment in mice lacking \u03b1-Synuclein","volume":"25","author":"Ellis","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2025.114692_bb0340","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/0024-3205(85)90146-8","article-title":"Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine","volume":"36","author":"Dot","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0345","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1471-4159.2003.02138.x","article-title":"Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe","volume":"88","author":"Champy","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.intimp.2025.114692_bb0350","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainresbull.2006.05.004","article-title":"Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice","volume":"70","author":"Eells","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.intimp.2025.114692_bb0355","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s11033-021-06343-8","article-title":"Pramipexole attenuates 6-OHDA-induced Parkinson\u2019s disease by mediating the Nurr1\/NF-\u03baB pathway","volume":"48","author":"Gao","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2025.114692_bb0360","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/cns.12536","article-title":"Nurr1-based therapies for Parkinson\u2019s disease","volume":"22","author":"Dong","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.intimp.2025.114692_bb0365","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1074\/jbc.M109.081125","article-title":"Direct transfer of \u03b1-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies","volume":"285","author":"Lee","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0370","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","article-title":"Activators and target genes of Rel\/NF-\u03baB transcription factors","volume":"18","author":"Pahl","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2025.114692_bb0375","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.neuropharm.2018.04.008","article-title":"Nurr1: a vital participant in the TLR4-NF-\u03baB signal pathway stimulated by \u03b1-synuclein in BV-2\u00a0cells","volume":"144","author":"Shao","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.intimp.2025.114692_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109986","article-title":"Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson\u2019s disease in rats: correlation between Nrf2 and HMGB1\/TLR4\/PI3K\/Akt\/mTOR signaling","volume":"117","author":"El-Sayed","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb0385","article-title":"Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats","volume":"146","author":"Abdelaziz","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2022.104846","article-title":"The PI3K-AKT pathway: a plausible therapeutic target in Parkinson\u2019s disease","volume":"129","author":"Goyal","year":"2023","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.intimp.2025.114692_bb0395","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/scitranslmed.3004676","article-title":"\u0391-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons","volume":"4","author":"Decressac","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0400","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BST20220770","article-title":"Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the \u03b1-synuclein accumulation in Parkinson\u2019s disease","volume":"51","author":"Er","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.intimp.2025.114692_bb0405","doi-asserted-by":"crossref","first-page":"12317","DOI":"10.1073\/pnas.1007088107","article-title":"NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection","volume":"107","author":"Volakakis","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0410","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1471-4159.2007.04494.x","article-title":"Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro","volume":"102","author":"Volpicelli","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.intimp.2025.114692_bb0415","doi-asserted-by":"crossref","first-page":"11351","DOI":"10.1074\/jbc.M111.272427","article-title":"Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival","volume":"287","author":"Barneda-Zahonero","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0420","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0959-4388(99)00048-3","article-title":"The GDNF Family Ligands and Receptors---Implications for Neural Development","volume":"10","author":"Baloh","year":"2000","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.intimp.2025.114692_bb0425","article-title":"A Nurr1 agonist causes neuroprotection in a parkinson\u2019s disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C)","volume":"10","author":"Smith","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.114692_bb0430","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1423-0127-21-27","article-title":"The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed","volume":"21","author":"Alavian","year":"2014","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0435","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neulet.2007.06.041","article-title":"Nurr1 is phosphorylated by ERK2 in vitro and its phosphorylation upregulates tyrosine hydroxylase expression in SH-SY5Y cells","volume":"423","author":"Zhang","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2025.114692_bb0440","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biocel.2011.09.007","article-title":"DJ-1 upregulates tyrosine hydroxylase gene expression by activating its transcriptional factor Nurr1 via the ERK1\/2 pathway","volume":"44","author":"Lu","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.intimp.2025.114692_bb0445","doi-asserted-by":"crossref","first-page":"10755","DOI":"10.1038\/s41598-020-67549-7","article-title":"Nurr1 performs its anti-inflammatory function by regulating RasGRP1 expression in neuro-inflammation","volume":"10","author":"Oh","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114692_bb0450","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncomms1272","article-title":"The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells","volume":"2","author":"Sekiya","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056595","article-title":"Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 Signalling","volume":"8","author":"Raveney","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.114692_bb0460","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/ni.2520","article-title":"Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis","volume":"14","author":"Sekiya","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.114692_bb0465","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.intimp.2018.12.019","article-title":"The mechanisms of NLRP3 inflammasome\/pyroptosis activation and their role in Parkinson\u2019s disease","volume":"67","author":"Wang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb0470","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbi.2024.03.038","article-title":"Pyroptosis-mediator GSDMD promotes Parkinson\u2019s disease pathology via microglial activation and dopaminergic neuronal death","volume":"119","author":"Zhang","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2025.114692_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2017.06.050","article-title":"Inflammation and mitochondrial dysfunction: a vicious circle in neurodegenerative disorders?","volume":"710","author":"van Horssen","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2025.114692_bb0480","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000511207","article-title":"Suppression of NLRP3 Inflammasome, Pyroptosis, and cell death by NIM811 in rotenone-exposed cells as an in vitro model of Parkinson\u2019s disease","volume":"20","author":"Zhang","year":"2021","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0485","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/ni.1980","article-title":"Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome","volume":"12","author":"Nakahira","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.114692_bb0490","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2012.01.009","article-title":"Oxidized mitochondrial DNA activates the NLRP3 Inflammasome during apoptosis","volume":"36","author":"Shimada","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.114692_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2020.102057","article-title":"Dysfunctional Nurr1 promotes high glucose-induced M\u00fcller cell activation by up-regulating the NF-\u03baB\/NLRP3 inflammasome axis","volume":"82","author":"Li","year":"2020","journal-title":"Neuropeptides"},{"key":"10.1016\/j.intimp.2025.114692_bb0500","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature25986","article-title":"Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1","volume":"556","author":"Mills","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.114692_bb0505","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/brainsci12091255","article-title":"Itaconate attenuates Neuroinflammation and exerts dopamine neuroprotection in Parkinson\u2019s disease through inhibiting NLRP3 Inflammasome","volume":"12","author":"Sun","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0510","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41401-022-00951-1","article-title":"Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson\u2019s disease","volume":"44","author":"Dong","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2025.114692_bb0515","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nn.2136","article-title":"Absolute requirement of GDNF for adult catecholaminergic neuron survival","volume":"11","author":"Pascual","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0520","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1016\/j.febslet.2015.11.006","article-title":"GDNF\u2013ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease","volume":"589","author":"Kramer","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.intimp.2025.114692_bb0525","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0304-3940(99)00443-7","article-title":"Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro","volume":"269","author":"Eggert","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2025.114692_bb0530","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1471-4159.1996.66010074.x","article-title":"Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium","volume":"66","author":"Hou","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.intimp.2025.114692_bb0535","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neuro.2015.10.011","article-title":"GDNF-induced cerebellar toxicity: a brief review","volume":"52","author":"Luz","year":"2016","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.intimp.2025.114692_bb0540","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2025.114692_bb0545","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson\u2019s disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2025.114692_bb0550","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Others, gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double- blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2025.114692_bb0555","first-page":"875","article-title":"GDNF and Parkinson\u2019s disease: where next?","volume":"10","author":"Barker","year":"2020","journal-title":"A Summary from a Recent Workshop, J Parkinsons Dis"},{"key":"10.1016\/j.intimp.2025.114692_bb0560","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/brain\/awr149","article-title":"GDNF fails to exert neuroprotection in a rat \u03b1-synuclein model of Parkinson\u2019s disease","volume":"134","author":"Decressac","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.intimp.2025.114692_bb0565","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nbd.2004.06.008","article-title":"Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson\u2019s disease","volume":"17","author":"Lo Bianco","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0570","doi-asserted-by":"crossref","first-page":"9248","DOI":"10.1523\/JNEUROSCI.1731-12.2012","article-title":"Conditional expression of Parkinson\u2019s disease-related mutant\u03b1-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1","volume":"32","author":"Lin","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009313","article-title":"Selective molecular alterations in the autophagy pathway in patients with lewy body disease and in models of \u03b1-synucleinopathy","volume":"5","author":"Crews","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.114692_bb0580","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00018-024-05419-5","article-title":"Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies","volume":"81","author":"Dai","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0585","series-title":"Nurr1 Regulates RET Expression in Dopamine Neurons of Adult Rat Midbrain","author":"Galleguillos","year":"2010"},{"key":"10.1016\/j.intimp.2025.114692_bb0590","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/cne.20828","article-title":"Nurr1 in Parkinson\u2019s disease and related disorders","volume":"494","author":"Chu","year":"2006","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.intimp.2025.114692_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2010.08.022","article-title":"\u0391-Synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson\u2019s disease","author":"Chu","year":"2011","journal-title":"Neurobiol"},{"key":"10.1016\/j.intimp.2025.114692_bb0600","doi-asserted-by":"crossref","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","article-title":"TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity","volume":"110","author":"Decressac","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0605","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1074\/jbc.C110.212589","article-title":"\u0391-Synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases","volume":"286","author":"Desplats","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0610","first-page":"872","article-title":"Phosphorylation does not prompt, nor prevent, the formation of \u03b1-synuclein toxic species in a rat model of Parkinson\u2019s disease","volume":"18","author":"da Silveira","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.intimp.2025.114692_bb0615","series-title":"Dopaminergic loss and inclusion body formation in \u03b1-synuclein mice: Implications for neurodegenerative disorders","author":"Masliah","year":"2000"},{"key":"10.1016\/j.intimp.2025.114692_bb0620","first-page":"53","article-title":"Subcellular localization of \u03b1-synuclein in primary neuronal cultures: effect of missense mutations","volume":"2000","author":"McLean","year":"2000","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.intimp.2025.114692_bb0625","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.mcn.2004.09.017","article-title":"Subcellular localisation of recombinant \u03b1- and \u03b3-synuclein","volume":"28","author":"Specht","year":"2005","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0630","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0304-3940(02)01258-2","article-title":"Phosphorylation of \u03b1-synuclein characteristic of synucleinopathy lesions is recapitulated in \u03b1-synuclein transgenic Drosophila","volume":"336","author":"Takahashi","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2025.114692_bb0635","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrneurol.2012.156","article-title":"Gene expression profiling in human neurodegenerative disease","volume":"8","author":"Cooper-Knock","year":"2012","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114692_bb0640","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(03)00420-3","article-title":"The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway","volume":"113","author":"Baker","year":"2003","journal-title":"Cell."},{"key":"10.1016\/j.intimp.2025.114692_bb0645","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","article-title":"\u0391-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity","volume":"15","author":"Kontopoulos","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.intimp.2025.114692_bb0650","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1523\/JNEUROSCI.5634-10.2011","article-title":"\u0391-Synuclein negatively regulates protein kinase C\u03b4 expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity","volume":"31","author":"Jin","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2012.05.024","article-title":"Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson\u2019s disease","author":"Siddiqui","year":"2012","journal-title":"Free Radic"},{"issue":"2007","key":"10.1016\/j.intimp.2025.114692_bb0660","first-page":"516","article-title":"Sirtuin 2 inhibitors rescue \u03b1-synuclein-mediated toxicity in models of Parkinson\u2019s disease","volume":"317","author":"Outeiro","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.114692_bb0665","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01992-1","article-title":"HDAC10 switches NLRP3 modification from acetylation to ubiquitination and attenuates acute inflammatory diseases","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.intimp.2025.114692_bb0670","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02956-x","article-title":"The role of Nurr1-miR-30e-5p-NLRP3 axis in inflammation-mediated neurodegeneration: insights from mouse models and patients\u2019 studies in Parkinson\u2019s disease","volume":"20","author":"Li","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2025.114692_bb0675","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.630536","article-title":"Nuclear receptors in the control of the NLRP3 Inflammasome pathway","volume":"12","author":"Duez","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.intimp.2025.114692_bb0680","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","article-title":"Inflammasome signalling in brain function and neurodegenerative disease","volume":"19","author":"Heneka","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0685","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3233\/JPD-223338","article-title":"Inflammasome activation in Parkinson\u2019s disease","volume":"12","author":"Jewell","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0690","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.114692_bb0695","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.630536","article-title":"Nuclear receptors in the control of the NLRP3 Inflammasome pathway","volume":"12","author":"Duez","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.intimp.2025.114692_bb0700","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.114692_bb0705","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41531-022-00293-z","article-title":"The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson\u2019s disease","volume":"8","author":"Pike","year":"2022","journal-title":"NPJ. Parkinsons Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0710","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/glia.23970","article-title":"\u0391-Synuclein evokes NLRP3 inflammasome-mediated IL-1\u03b2 secretion from primary human microglia","volume":"69","author":"Pike","year":"2021","journal-title":"Glia"},{"key":"10.1016\/j.intimp.2025.114692_bb0715","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/35006074","article-title":"Drosophila model of Parkinson\u2019s disease","volume":"404","author":"Feany","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.114692_bb0720","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1021\/acschemneuro.9b00092","article-title":"Identification of a new \u03b1-Synuclein aggregation inhibitor via mass spectrometry based screening","volume":"10","author":"Xu","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"2002","key":"10.1016\/j.intimp.2025.114692_bb0725","first-page":"865","article-title":"Chaperone suppression of \u03b1-synuclein toxicity in a Drosophila model for Parkinson\u2019s disease","volume":"295","author":"Auluck","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.114692_bb0730","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-Synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.114692_bb0735","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12031-002-0012-8","article-title":"Development of a new treatment for Alzheimer\u2019s disease and Parkinson\u2019s disease using anti-aggregatory \u03b2-synuclein-derived peptides","volume":"19","author":"Windisch","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0740","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1021\/bi0600749","article-title":"Small molecule inhibitors of \u03b1-synuclein filament assembly","volume":"45","author":"Masuda","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2025.114692_bb0745","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/ijms18030478","article-title":"High-throughput screening methodology to identify alpha-synuclein aggregation inhibitors","volume":"18","author":"Pujols","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb0750","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nm0602-600","article-title":"Dopamine-dependent neurotoxicity of \u03b1-synuclein: a mechanism for selective neurodegeneration in Parkinson disease","volume":"8","author":"Xu","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0755","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41598-021-04131-9","article-title":"Two-step screening method to identify \u03b1-synuclein aggregation inhibitors for Parkinson\u2019s disease","volume":"12","author":"Hideshima","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114692_bb0760","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.slasd.2022.05.001","article-title":"A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins","volume":"27","author":"Casalino","year":"2022","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.intimp.2025.114692_bb0765","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting a-Synuclein for Parkinson\u2019s disease","volume":"74","author":"Jasutkar","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2025.114692_bb0770","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2025.114692_bb0775","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","article-title":"The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils","volume":"13","author":"Antonschmidt","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0780","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","article-title":"The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset","volume":"127","author":"Levin","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2025.114692_bb0785","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson\u2019s disease model","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2025.114692_bb0790","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fnins.2016.00099","article-title":"Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy","volume":"10","author":"Fellner","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0795","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","author":"Heras-Garvin","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2025.114692_bb0800","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40035-020-00217-y","article-title":"Targeting \u03b1-synuclein by PD03 AFFITOPE\u00ae and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance","volume":"9","author":"Lemos","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.intimp.2025.114692_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104021","article-title":"Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial","volume":"80","author":"Levin","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2025.114692_bb0810","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1021\/acschemneuro.2c00355","article-title":"Phosphatidylcholine and phosphatidylserine uniquely modify the secondary structure of \u03b1-Synuclein oligomers formed in their presence at the early stages of protein aggregation","volume":"13","author":"Dou","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0815","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.680026","article-title":"Squalamine and its derivatives modulate the aggregation of amyloid-\u03b2 and \u03b1-Synuclein and suppress the toxicity of their oligomers","volume":"15","author":"Limbocker","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0820","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of \u03b1-synuclein aggregation & suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0825","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3233\/JPD-202076","article-title":"Squalamine restores the function of the enteric nervous system in mouse models of Parkinson\u2019s disease","volume":"10","author":"West","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0830","first-page":"1666","article-title":"Oral ENT-01 targets enteric neurons to treat constipation in Parkinson disease a randomized controlled trial","volume":"176","author":"Camilleri","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0835","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1039\/D1NP00042J","article-title":"Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic","volume":"39","author":"Limbocker","year":"2021","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.intimp.2025.114692_bb0840","article-title":"Multistep inhibition of \u03b1-Synuclein aggregation and toxicity in vitro and in vivo by Trodusquemine","author":"Perni","year":"2018","journal-title":"Biol"},{"key":"10.1016\/j.intimp.2025.114692_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.113115","article-title":"Reorganization of the outer layer of a model of the plasma membrane induced by a neuroprotective aminosterol","volume":"222","author":"Barletti","year":"2023","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.intimp.2025.114692_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2020.11.005","article-title":"The library derived 4554W peptide inhibits primary nucleation of \u03b1-Synuclein","volume":"432","author":"Meade","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.intimp.2025.114692_bb0855","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46775","article-title":"Inhibition of synucleinopathic seeding by rationally designed inhibitors","volume":"9","author":"Sangwan","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.intimp.2025.114692_bb0860","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s42003-021-01746-6","article-title":"Development of an \u03b1-synuclein knockdown peptide and evaluation of its efficacy in Parkinson\u2019s disease models","volume":"4","author":"Jin","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.intimp.2025.114692_bb0865","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.659926","article-title":"Identification of two novel peptides that inhibit \u03b1-Synuclein toxicity and aggregation","volume":"14","author":"Popova","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0870","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1073\/pnas.1808845116","article-title":"\u0391-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson\u2019s disease","volume":"116","author":"Levine","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0875","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1038\/s41467-022-31790-7","article-title":"Heparin induces \u03b1-synuclein to form new fibril polymorphs with attenuated neuropathology","volume":"13","author":"Tao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0880","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0885","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03270-6","article-title":"Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0890","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of Cinpanemab in Early Parkinson\u2019s Disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0895","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209137","article-title":"Cinpanemab in early Parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial","volume":"102","author":"Hutchison","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2025.114692_bb0900","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/mds.29016","article-title":"A randomized first-in-human study with UB-312, a UBITh\u00ae \u03b1-Synuclein peptide vaccine","volume":"37","author":"Yu","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2025.114692_bb0905","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-023-00552-7","article-title":"In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson\u2019s disease","volume":"9","author":"Price","year":"2023","journal-title":"NPJ. Parkinsons Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb0910","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/mds.29170","article-title":"Phase 1\/1b studies of UCB0599, an Oral inhibitor of \u03b1-Synuclein Misfolding, including a randomized study in Parkinson\u2019s disease","volume":"37","author":"Smit","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2025.114692_bb0915","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson\u2019s disease model","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2025.114692_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104021","article-title":"Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial","volume":"80","author":"Levin","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2025.114692_bb0925","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2025.114692_bb0930","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-Synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2025.114692_bb0935","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.7326\/M22-1438","article-title":"Oral ENT-01 targets enteric neurons to treat constipation in Parkinson disease\u00a0: a randomized controlled trial","volume":"175","author":"Camilleri","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb0940","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.680026","article-title":"Squalamine and its derivatives modulate the aggregation of amyloid-\u03b2 and \u03b1-Synuclein and suppress the toxicity of their oligomers","volume":"15","author":"Limbocker","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb0945","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","article-title":"Multistep inhibition of \u03b1-Synuclein aggregation and toxicity in vitro and in vivo by Trodusquemine","volume":"13","author":"Perni","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.intimp.2025.114692_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00544","article-title":"Fasudil inhibits \u03b1-synuclein aggregation through ROCK-inhibition-mediated mechanisms","author":"Lage","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.intimp.2025.114692_bb0955","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/01616412.2021.2024715","article-title":"Neuroprotective effects of catechins in an experimental Parkinson\u2019s disease model and SK-N-AS cells: evaluation of cell viability, anti-inflammatory and anti-apoptotic effects","volume":"44","author":"\u00d6zduran","year":"2022","journal-title":"Neurol. Res."},{"key":"10.1016\/j.intimp.2025.114692_bb0960","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/WNR.0000000000001149","article-title":"Effects and mechanism of epigallocatechin-3-gallate on apoptosis and mTOR\/AKT\/GSK-3\u03b2 pathway in substantia nigra neurons in Parkinson rats","volume":"30","author":"Zhou","year":"2019","journal-title":"Neuroreport"},{"key":"10.1016\/j.intimp.2025.114692_bb0965","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/s41467-025-56737-6","article-title":"Aspirin inhibits proteasomal degradation and promotes \u03b1-synuclein aggregate clearance through K63 ubiquitination","volume":"16","author":"Gao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0970","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cbi.2017.03.016","article-title":"Protective role of apigenin on rotenone induced rat model of Parkinson\u2019s disease: suppression of neuroinflammation and oxidative stress mediated apoptosis","volume":"269","author":"Anusha","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.intimp.2025.114692_bb0975","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18689-x","article-title":"CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson\u2019s disease","volume":"11","author":"Bengoa-Vergniory","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101902","article-title":"The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple \u03b1-synuclein strains","volume":"298","author":"Pe\u00f1a-D\u00edaz","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb0985","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1073\/pnas.1804198115","article-title":"Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons","volume":"115","author":"Pujols","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb0990","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/brain\/awab214","article-title":"NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson\u2019s disease","volume":"144","author":"Khan","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.intimp.2025.114692_bb0995","series-title":"Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data, Npj Parkinson\u2019s Disease 2025 11","first-page":"1","volume":"1 11","author":"Xiao","year":"2025"},{"key":"10.1016\/j.intimp.2025.114692_bb1000","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb1005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb1010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb1015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-016-0094-3","article-title":"MicroRNA-7 targets nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson\u2019s disease","volume":"11","author":"Zhou","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.intimp.2025.114692_bb1020","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1007\/s12035-015-9620-5","article-title":"MicroRNA-7 enhances subventricular zone neurogenesis by inhibiting NLRP3\/Caspase-1 Axis in adult neural stem cells","volume":"53","author":"Fan","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2025.114692_bb1025","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11481-019-09843-4","article-title":"FTY720 inhibits MPP+-induced microglial activation by affecting NLRP3 Inflammasome activation","volume":"14","author":"Yao","year":"2019","journal-title":"J. NeuroImmune Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114692_bb1030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25767-1","article-title":"Selective targeting of the TLR2\/MyD88\/NF-\u03baB pathway reduces \u03b1-synuclein spreading in vitro and in vivo","volume":"12","author":"Dutta","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104538","article-title":"Caffeic acid reduces A53T \u03b1-synuclein by activating JNK\/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease","volume":"150","author":"Zhang","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2025.114692_bb1040","article-title":"Controlled activation of TRPV1 channels on microglia to boost their autophagy for clearance of alpha-Synuclein and enhance therapy of Parkinson\u2019s disease","volume":"34","author":"Yuan","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.intimp.2025.114692_bb1045","author":"Study Details"},{"key":"10.1016\/j.intimp.2025.114692_bb1055","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3233\/JPD-240353","article-title":"Clinical trial highlights: anti-inflammatory and immunomodulatory agents","volume":"14","author":"Patel","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110063","article-title":"Inhibition of NLRP3 inflammasome ameliorates LPS-induced neuroinflammatory injury in mice via PINK1\/Parkin pathway","volume":"257","author":"Wang","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.intimp.2025.114692_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577543","article-title":"A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson\u2019s disease","volume":"354","author":"Huang","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2025.114692_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175931","article-title":"Research progress of NLRP3 inflammasome and its inhibitors with aging diseases","volume":"957","author":"Yuan","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb1075","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13789","article-title":"First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor","volume":"17","author":"Gatlik","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb1080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuroscience.2022.06.036","article-title":"Cannabidiol alleviates the damage to dopaminergic neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced Parkinson\u2019s disease mice via regulating neuronal apoptosis and Neuroinflammation","volume":"498","author":"Wang","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.intimp.2025.114692_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114201","article-title":"Irisin promotes autophagy and attenuates NLRP3 inflammasome activation in Parkinson\u2019s disease","volume":"149","author":"Zhu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.118042","article-title":"Discovery of 2-(6-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5-dimethylpyridazin-3-yl)-5-(trifluoromethyl)phenol (ASP0965): a potent, orally active and brain-penetrable NLRP3 inflammasome inhibitor with a novel scaffold for the treatment of \u03b1-synucleinopathy","volume":"118","author":"Inagaki","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb1095","series-title":"Neuroprotective Role of Carvacrol Via Nrf2\/HO-1\/NLRP3 axis in Rotenone-Induced PD Mice Model, Brain Res 1836","author":"Shah","year":"2024"},{"key":"10.1016\/j.intimp.2025.114692_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113716","article-title":"Crosstalk between SIRT1\/Nrf2 signaling and NLRP3 inflammasome\/pyroptosis as a mechanistic approach for the neuroprotective effect of linagliptin in Parkinson\u2019s disease","volume":"145","author":"Ghaith","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106955","article-title":"Brassisterol a, a new ergosterol from co-cultivation of fungi attenuates neuroinflammation via targeting NLRP3\/caspase-1\/GSDMD pathway","volume":"142","author":"Tong","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155230","article-title":"Echinacoside exerts neuroprotection via suppressing microglial \u03b1-synuclein\/TLR2\/NF-\u03baB\/NLRP3 axis in parkinsonian models","volume":"123","author":"Yang","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.114692_bb1115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainresbull.2020.08.015","article-title":"Echinacoside protects dopaminergic neurons by inhibiting NLRP3\/Caspase-1\/IL-1\u03b2 signaling pathway in MPTP-induced Parkinson\u2019s disease model","volume":"164","author":"Gao","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.intimp.2025.114692_bb1120","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02830-w","article-title":"Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease","volume":"20","author":"Amo-Aparicio","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2025.114692_bb1125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.794770","article-title":"Dl-3-n-butylphthalide rescues dopaminergic neurons in Parkinson\u2019s disease models by inhibiting the NLRP3 Inflammasome and ameliorating mitochondrial impairment","volume":"12","author":"Que","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114692_bb1130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2021.05.008","article-title":"Inhibition of NLRP3 inflammasome by glibenclamide attenuated dopaminergic neurodegeneration and motor deficits in paraquat and maneb-induced mouse Parkinson\u2019s disease model","volume":"349","author":"Qiu","year":"2021","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.intimp.2025.114692_bb1135","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11481-019-09843-4","article-title":"FTY720 inhibits MPP+-induced microglial activation by affecting NLRP3 Inflammasome activation","volume":"14","author":"Yao","year":"2019","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb1140","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-1036-x","article-title":"Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia","volume":"14","author":"Fan","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2025.114692_bb1145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbi.2020.09.017","article-title":"Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease","volume":"91","author":"Ahmed","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2025.114692_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107432","article-title":"GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson\u2019s disease animal models","volume":"209","author":"Ha","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2025.114692_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.149129","article-title":"A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson\u2019s disease","volume":"1842","author":"Chatterjee","year":"2024","journal-title":"Brain Res."},{"key":"10.1016\/j.intimp.2025.114692_bb1160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2009.01.038","article-title":"A Nurr1\/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death","volume":"137","author":"Saijo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.114692_bb1165","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bbrc.2016.12.034","article-title":"Nurr1 overexpression exerts neuroprotective and anti-inflammatory roles via down-regulating CCL2 expression in both in vivo and in vitro Parkinson\u2019s disease models","volume":"482","author":"Liu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb1170","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.1073\/pnas.1509742112","article-title":"Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson\u2019s disease","volume":"112","author":"Kim","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb1175","doi-asserted-by":"crossref","first-page":"14370","DOI":"10.1523\/JNEUROSCI.1155-15.2015","article-title":"Nurr1 and retinoid X receptor ligands stimulate ret signaling in dopamine neurons and can alleviate \u03b1-synuclein disrupted gene expression","volume":"35","author":"Volakakis","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb1180","article-title":"Enhancing beta-catenin activity via GSK3beta inhibition protects PC12 cells against rotenone toxicity through Nurr1 induction","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.114692_bb1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115566","article-title":"Want of Wnt in Parkinson\u2019s disease: could sFRP disrupt interplay between Nurr1 and Wnt signaling?","volume":"212","author":"Gamit","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb1190","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuroscience.2016.10.029","article-title":"Protective effects of a herbal extract combination of Bupleurum falcatum, Paeonia suffruticosa, and Angelica dahurica against MPTP-induced neurotoxicity via regulation of nuclear receptor-related 1 protein","volume":"340","author":"Sim","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.intimp.2025.114692_bb1195","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1476-5381.2011.01817.x","article-title":"Prostanoid EP1 receptors mediate up-regulation of the orphan nuclear receptor Nurr1 by cAMP-independent activation of protein kinase a, CREB and NF-\u03baB","volume":"166","author":"Ji","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb1200","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1210\/mend.16.7.0863","article-title":"Activation and induction of NUR77\/NURR1 in Corticotrophs by CRH\/cAMP: involvement of calcium, protein kinase a, and MAPK pathways","volume":"16","author":"Kovalovsky","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.intimp.2025.114692_bb1205","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/ijc.25600","article-title":"VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: role in VEGF-induced angiogenesis","volume":"128","author":"Zhao","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2025.114692_bb1210","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1471-2202-10-146","article-title":"Activation of retinoid X receptor increases dopamine cell survival in models for Parkinson\u2019s disease","volume":"10","author":"Friling","year":"2009","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb1215","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/NEN.0b013e31822830e5","article-title":"Signaling of glial cell line-derived neurotrophic factor and its receptor GFR\u03b11 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease","volume":"70","author":"Lei","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.intimp.2025.114692_bb1220","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0896-6273(02)00828-0","article-title":"Function and regulation of CREB family transcription factors in the nervous system","volume":"35","author":"Lonze","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.intimp.2025.114692_bb1225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3727\/096368911X580572","article-title":"Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology","volume":"21","author":"Chang","year":"2012","journal-title":"Cell Transplant."},{"key":"10.1016\/j.intimp.2025.114692_bb1230","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/cn400100f","article-title":"Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson\u2019s disease","volume":"4","author":"McFarland","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb1235","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s12035-021-02709-y","article-title":"Retinoid X receptor: cellular and biochemical roles of nuclear receptor with a focus on neuropathological involvement","volume":"59","author":"Sharma","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2025.114692_bb1240","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neuropharm.2013.05.025","article-title":"Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of a-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL\/6J mice","volume":"73","author":"Sathiya","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.intimp.2025.114692_bb1245","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1271\/bbb.100165","article-title":"A detoxified extract of rhus verniciflua stokes upregulated the expression of BDNF and GDNF in the rat brain and the human dopaminergic cell line SH-SY5Y","volume":"74","author":"Sapkota","year":"2010","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.intimp.2025.114692_bb1250","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000077451","article-title":"Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture","volume":"71","author":"Ohta","year":"2004","journal-title":"Pharmacology"},{"key":"10.1016\/j.intimp.2025.114692_bb1255","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/carcin\/bgp161","article-title":"Activation of thromboxane A2 receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells","volume":"30","author":"Li","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.intimp.2025.114692_bb1260","doi-asserted-by":"crossref","first-page":"11351","DOI":"10.1074\/jbc.M111.272427","article-title":"Nurr1 protein is required for N-methyl\u2011d-aspartic acid (NMDA) receptor-mediated neuronal survival","volume":"287","author":"Barneda-Zahonero","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.114692_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136045","article-title":"Nurr1 downregulation is caused by CREB inactivation in a Parkinson\u2019s disease mouse model","volume":"759","author":"Xu","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2025.114692_bb1270","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/hmg\/ddt484","article-title":"WNT\/\u03b2-catenin signalling is activated in aldosteroneproducing adenomas and controls aldosterone production","volume":"23","author":"Berthon","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.intimp.2025.114692_bb1275","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/stem.1708","article-title":"Wnt\/\u03b2-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson\u2019s disease","volume":"32","author":"L\u2019Episcopo","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.intimp.2025.114692_bb1280","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1476-5381.2012.01846.x","article-title":"A prolyl oligopeptidase inhibitor, KYP-2047, reduces \u03b1-synuclein protein levels and aggregates in cellular and animal models of Parkinson\u2019s disease","volume":"166","author":"My\u00f6h\u00e4nen","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114692_bb1285","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/acschemneuro.8b00460","article-title":"Altered expression levels of MicroRNA-132 and Nurr1 in peripheral blood of Parkinson\u2019s disease: potential disease biomarkers","volume":"10","author":"Yang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.intimp.2025.114692_bb1290","first-page":"1673","article-title":"miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression","volume":"125","author":"Yang","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.intimp.2025.114692_bb1295","first-page":"1","article-title":"MicroRNAs regulation in Parkinson\u2019s disease, and their potential role as diagnostic and therapeutic targets","volume":"10","author":"Shaheen","year":"2024","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"10.1016\/j.intimp.2025.114692_bb1300","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/stem.294","article-title":"Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival","volume":"28","author":"Lee","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.intimp.2025.114692_bb1305","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3727\/096368914X685078","article-title":"A high-efficiency induction of dopaminergic cells from human umbilical mesenchymal stem cells for the treatment of hemiparkinsonian rats","volume":"24","author":"Ko","year":"2015","journal-title":"Cell Transplant."},{"key":"10.1016\/j.intimp.2025.114692_bb1310","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/cns.13149","article-title":"Transplantation of Nurr1-overexpressing neural stem cells and microglia for treating parkinsonian rats","volume":"26","author":"Qian","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.intimp.2025.114692_bb1315","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1474-4422(11)70097-7","article-title":"Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson\u2019s disease: a double-blind, randomised, controlled trial","volume":"10","author":"Gross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2025.114692_bb1325","author":"Biopharma"},{"key":"10.1016\/j.intimp.2025.114692_bb1330","first-page":"1","article-title":"An optimized Nurr1 agonist provides disease-modifying effects in Parkinson\u2019s disease models","volume":"14","author":"Kim","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.114692_bb1335","article-title":"A Nurr1 agonist causes neuroprotection in a Parkinson\u2019s disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C)","volume":"10","author":"Smith","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.114692_bb1340","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1007\/s12035-015-9477-7","article-title":"Contra-directional coupling of Nur77 and Nurr1 in neurodegeneration: a novel mechanism for Memantine-induced anti-inflammation and anti-mitochondrial impairment","volume":"53","author":"Wei","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2025.114692_bb1345","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1007\/s12035-018-0923-1","article-title":"Cilostazol mediated Nurr1 and autophagy enhancement: neuroprotective activity in rat rotenone PD model","volume":"55","author":"Hedya","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2025.114692_bb1350","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1073\/pnas.1616874114","article-title":"Nurr1:RXR\u03b1 heterodimer activation as monotherapy for Parkinson\u2019s disease","volume":"114","author":"Spathis","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb1355","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.18632\/oncotarget.7191","article-title":"Selective brain penetrable Nurr1 transactivator for treating Parkinson\u2019s disease","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2025.114692_bb1360","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuroscience.2016.10.029","article-title":"Protective effects of a herbal extract combination of Bupleurum falcatum, Paeonia suffruticosa, and Angelica dahurica against MPTP-induced neurotoxicity via regulation of nuclear receptor-related 1 protein","volume":"340","author":"Sim","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.intimp.2025.114692_bb1365","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.neuint.2009.07.009","article-title":"Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice","volume":"55","author":"Inden","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.intimp.2025.114692_bb1370","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ptr.3592","article-title":"Moracenin D from Mori cortex radicis protects SH-SY5Y cells against dopamine-induced cell death by regulating nurr1 and \u03b1-synuclein expression","volume":"26","author":"Ham","year":"2012","journal-title":"Phytother. Res."},{"key":"10.1016\/j.intimp.2025.114692_bb1375","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-Synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.114692_bb1380","doi-asserted-by":"crossref","DOI":"10.1016\/j.dscb.2024.100163","article-title":"Novel approaches targeting \u03b1-Synuclein for Parkinson\u2019s disease: current progress and future directions for the disease-modifying therapies","volume":"16","author":"Baggett","year":"2024","journal-title":"Brain Disord"},{"key":"10.1016\/j.intimp.2025.114692_bb1385","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jneuroim.2019.02.010","article-title":"A Nurr1 agonist amodiaquine attenuates inflammatory events and neurological deficits in a mouse model of intracerebral hemorrhage","volume":"330","author":"Kinoshita","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2025.114692_bb1390","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.114692_bb1395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-023-02830-w","article-title":"Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease","volume":"20","author":"Amo-Aparicio","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2025.114692_bb1400","first-page":"335","article-title":"Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyond","volume":"1","author":"Latchney","year":"2012","journal-title":"Eur J Neurodegener Dis"},{"key":"10.1016\/j.intimp.2025.114692_bb1405","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11011-021-00670-2","article-title":"The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson\u2019s disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K\/AKT signaling pathway","volume":"36","author":"Kambey","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.intimp.2025.114692_bb1410","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209137","article-title":"Cinpanemab in early Parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial","volume":"102","author":"Hutchison","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2025.114692_bb1415","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009399","article-title":"\u0391-Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.intimp.2025.114692_bb1420","doi-asserted-by":"crossref","unstructured":"G. Pagano, K.I. Taylor, J. Anzures Cabrera, T. Simuni, K. Marek, R.B. Postuma, N. Pavese, F. Stocchi, K. Brockmann, H. Svoboda, D. Trundell, A. Monnet, R. Doody, P. Fontoura, G.A. Kerchner, P. Brundin, T. Nikolcheva, A. Bonni, Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease, Nature Medicine 2024 30:4 30 (2024) 1096\u20131103. Doi: https:\/\/doi.org\/10.1038\/s41591-024-02886-y.","DOI":"10.1038\/s41591-024-02886-y"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T23:31:05Z","timestamp":1747265465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925006824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":282,"alternative-id":["S1567576925006824"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114692","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson's disease: From pathogenesis to potential therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114692"}}